Summary : hC Bioscience, Inc., a company focused on discovering and developing tRNA-based therapies, announced that it has raised $24 million in…
February 2022
-
-
Global Market
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea
by adminby adminSummary : LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational…
-
CANbridge Pharmaceuticals Inc.CompaniesPharma Science & ResearchRegulatoryU.S FDA
CANbridge Announces Approval of CAN108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone
by adminby adminSummary : CANbridge Pharmaceuticals, Inc. (“CANbridge”, stock code 1228.HK), a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development…
-
Summary : Alejandro Antalich, Chief Executive Officer and Director of Biomind Labs, said: “We are pleased to have obtained our DTC eligibility,…
-
Merger / Acquisition
c-LEcta Announces That It Has Reached Agreement to Be Acquired by Kerry Group
by adminby adminSynopsis : Kerry Group acquires majority of the shares of c-LEcta GmbH. The previous management of c-LEcta remains on board. Acquisition promotes…
-
Pharma Science & Research
American Oncology Network (AON) and VieCure Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
by adminby adminSummary : Collaboration offers clinicians access to a state-of-the-art, cloud based oncology decision support platform that fully integrates the latest codified clinical…
-
Global MarketLaunchRegulatory
Gunze Launches TENALEAF™ Absorbable Adhesion Barrier in Japan
by adminby adminSummary : Gunze Limited (Headquarters: Osaka, Japan, President: Toshiyasu Saguchi) [TOKYO: 3002] is pleased to announce that Gunze has obtained medical device…
-
Global Market
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
by adminby adminSummary : Topline data of the main cohort of AAVance clinical trial expected in Q3 2022 Stabilization or decreased size of white…
-
Global MarketModerna
Moderna Cleared to Bring RSV Vaccine to Pivotal Phase III Trial
by adminby adminSummary : Moderna is poised to begin Phase III of its pivotal clinical trial for its candidate vaccine for respiratory syncytial virus…
-
AstraZenecaCompaniesGlobal MarketPharma Science & Research
AstraZeneca in the News: EMA Greenlights RSV Vaccine, Leif Johansson Departing
by adminby adminSummary : AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency. Nirsevimab was…